[{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eckert & Ziegler Strahlen \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Eckert & Ziegler Strahlen \/ POINT Biopharma"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"TLX592","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"177Lu-Satoreotide Tetraxetan","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Eckert & Ziegler Strahlen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Eckert & Ziegler will supply Ariceum with n.c.a. Ac-225 and Lu-177 used to radiolabel Ariceum's proprietary lead radiopharmaceutical drug SS0110 (satoreotide) targeting hard-to-treat cancers.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          December 05, 2024

                          Lead Product(s) : 177Lu-Satoreotide Tetraxetan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Ariceum Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : The partnership aims to provide Telix with both an additional commercial source of 225Ac and access to a platform technology for use in the development of next generation TATs, including TLX592.

                          Product Name : TLX592

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 13, 2024

                          Lead Product(s) : TLX592

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Telix Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Under the agreement, Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands, including PSMA-targeted PNT2001 program.

                          Product Name : PNT2001

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 04, 2023

                          Lead Product(s) : PNT2001

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Point Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank